论文部分内容阅读
急性心肌梗塞溶栓研究的第一阶段已得出结论。普遍认为,静脉输注链激酶可溶解冠状动脉内血栓,导致再灌注和改善左心室功能;更重要的是减少了死亡率。当然患者幸存可能是由于排除了血凝块,但其它因素也可能发挥了作用,例如血液粘滞性和血压的改变以及全身性抗凝治疗。但静脉输注链激酶有其局限性。它具有抗原性,引起变态反应、低血压和心动迟缓。另外,再灌注的成功率随时间而定,并在4～6小时后下降,因此,由于放置心脏导管的推迟,否定了冠状动脉内治疗可能具有的任
The first phase of an acute myocardial infarction thrombolytic study has concluded. It is generally accepted that intravenous streptokinase dissolves coronary thrombi, leading to reperfusion and improving left ventricular function; and more importantly, reducing mortality. Of course, the survival of patients may be due to the exclusion of blood clots, but other factors may also play a role, such as changes in blood viscosity and blood pressure and systemic anticoagulant therapy. But intravenous streptokinase has its limitations. It has antigenicity, causes allergy, hypotension and bradycardia. In addition, the success rate of reperfusion is time dependent and decreases after 4 to 6 hours, thus negating the potential for intracoronary treatment due to the delay in placement of a cardiac catheter